Microbio is pleased to have its collaboration with QUT, DSTG and DMTC Ltd highlighted in the 2021 DMTC Annual Report. See page 27 for the write up.
Microbio is pleased to share this profile published in The Yield, Spoke Corporate’s Investor and Industry News. Author Simon Shepherdson has perfectly captured Microbio’s exciting history and big plans for the future. https://spokecorporate.com/diagnostic-technology-set-to-change-the-world/
Microbio is pleased to share the Case Study published by Life Sciences Queensland detailing the recent Federal Government Accelerating Commercialisation Grant and commercialisation progress of its pathogen detection products. Read more at: https://www.lsq.com.au/case-study/microbio-new-diagnostic-tests-to-improve-the-identification-of-pathogens/
Microbio Pty Ltd, an Australian-owned biotech company has been awarded a Federal Government Accelerating Commercialisation Grant to commercialise Microbio’s InfectID-Blood Stream Infection (BSI) diagnostic assay. Read more in the full media release.
Microbio has developed a new type of COVID-19 test that has the potential to determine not only if someone has the virus but also if they are infectious.
Microbio today announced its ground-breaking InfectID-COVID-19-R test which has been independently validated to identify the presence of replication-competent SARS-CoV-2 virus in samples in 45 minutes (post RNA extraction).
Dr Flavia Huygens has been honoured with one of DMTC’s 2020 Excellence Awards. Dr Huygens received the Project Leadership Award: “In recognition of exemplary professional conduct in support of DMTC’s objectives.”
The awards evening was held during the DMTC Annual Conference, 11-12 March 2020 in Canberra. The conference highlights the projects building defence and national security capabilities through collaboration with industry.
Dr Huygens was also invited to present at the conference to share progress on a project to develop a highly sensitive and specific pathogen identification diagnostic test. This project is a collaboration between DMTC Ltd, Microbio and Queensland University of Technology.
The DMTC Medical Countermeasures Program has featured the collaboration with Microbio in the 2019 Annual Report. The collaboration aims to refine InfectID to diagnose seven security sensitive biological agents (SSBAs) without culture, so the technology can be used in field deployable clinical settings.
https://issuu.com/dmtc-ltd/docs/dmtc_annual_report_2019 (see page 39)